---
schema_version: "secwatch.filing_event.v1"
accession: "0000059478-25-000129"
form_type: "8-K"
ticker: "LLY"
cik: "0000059478"
company_name: "ELI LILLY & Co"
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-23T01:23:46.089907+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Lilly Q1 revenue up 45% to $12.73B; EPS beat; reaffirms guidance

## Summary
- Revenue $12.73B (+45% YoY) driven by Mounjaro and Zepbound volume growth.
- Reported EPS $3.06 (+23%); non-GAAP EPS $3.34 (+29%), including $1.72 IPR&D charges.
- Revenue guidance reaffirmed at $58.0-$61.0 billion for full-year 2025.
- Pipeline: positive Phase 3 for oral GLP-1 orforglipron in T2D; approvals in oncology/immunology.

## SEC filing metadata
- accession: 0000059478-25-000129
- form_type: 8-K
- ticker: LLY
- cik: 0000059478
- company_name: ELI LILLY & Co
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/59478/000005947825000129/0000059478-25-000129-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/59478/000005947825000129/lly-20250501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000059478-25-000129
- JSON: https://secwatch.observer/filing/0000059478-25-000129.json
- Plain text: https://secwatch.observer/filing/0000059478-25-000129.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.